Story
Cerebras Stock Plummets on Report of OpenAI Shift to Nvidia GPUs

Summary
Shares of AI chipmaker Cerebras Systems fell sharply after a research firm reported OpenAI is using Nvidia hardware for its latest model, raising investor concerns about a crucial multi-billion dollar partnership.
Shares of AI chipmaker Cerebras Systems (CBRS) plunged more than 8% on Monday after a report from a semiconductor research firm alleged that key customer OpenAI has opted to use rival Nvidia (NVDA) GPUs for its newest flagship model, casting doubt on the company's core partnership.
Key Partnership Questioned
The sell-off was triggered by a post on the social media platform X from semiconductor research firm SemiAnalysis. The firm stated that OpenAI's newly unveiled GPT-6.1 Sol Ultrafast model is running on Nvidia GPUs, specifically at low batch sizes. This marks a potential departure from the prior-generation model, GPT-5.6 Sol Ultrafast, which was powered by Cerebras hardware.
The report raises critical questions for investors about the status of the $20 billion multi-year deal between Cerebras and OpenAI, which has been a cornerstone of the chipmaker's valuation. Neither Cerebras nor OpenAI has issued an official statement confirming or denying the report.
Market Impact and Competitive Threat
AdThe market reacted swiftly to the news, with Cerebras stock falling to $178.71, approaching its 52-week low of $160.81. The drop was a notable underperformance against the broader market, as the Nasdaq was trading higher on the day.
The core of the concern lies in the potential erosion of Cerebras's competitive moat. The company's investment thesis is built on its Wafer-Scale Engine (WSE), a single, massive chip designed to eliminate the latency of communication between multiple GPUs. If Nvidia's latest platforms, such as its Blackwell architecture, can now match Cerebras's performance on low-latency tasks, the specialized premium Cerebras commands could be at risk.
Context for Investors
The uncertainty adds to existing investor concerns, which include approximately $266 million in insider share sales over the past three months and the company's lack of profitability. Cerebras posted a GAAP net loss of $450.5 million in its most recent quarter. Until the companies provide clarity on the hardware stack for GPT-6.1, the ambiguity surrounding its most important customer relationship will likely continue to weigh on Cerebras's stock.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.

Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.